Literature DB >> 28751457

2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.

Ana Feliú1, Itziar Bonilla Del Río2,3, Francisco Javier Carrillo-Salinas1, Gloria Hernández-Torres4, Leyre Mestre1, Nagore Puente2,3, Silvia Ortega-Gutiérrez4, Maria L López-Rodríguez4, Pedro Grandes2,3,5, Miriam Mecha6, Carmen Guaza6.   

Abstract

The failure to undergo remyelination is a critical impediment to recovery in multiple sclerosis. Chondroitin sulfate proteoglycans (CSPGs) accumulate at demyelinating lesions creating a nonpermissive environment that impairs axon regeneration and remyelination. Here, we reveal a new role for 2-arachidonoylglycerol (2-AG), the major CNS endocannabinoid, in the modulation of CSPGs deposition in a progressive model of multiple sclerosis, the Theiler's murine encephalomyelitis virus-induced demyelinating disease. Treatment with a potent reversible inhibitor of the enzyme monoacylglycerol lipase, which accounts for 85% of the 2-AG degradation in the mouse CNS, modulates neuroinflammation and reduces CSPGs accumulation and astrogliosis around demyelinated lesions in the spinal cord of Theiler's murine encephalomyelitis virus-infected mice. Inhibition of 2-AG hydrolysis augments the number of mature oligodendrocytes and increases MBP, leading to remyelination and functional recovery of mice. Our findings establish a mechanism for 2-AG promotion of remyelination with implications in axonal repair in CNS demyelinating pathologies.SIGNIFICANCE STATEMENT The deposition of chondroitin sulfate proteoglycans contributes to the failure in remyelination associated with multiple sclerosis. Here we unveil a new role for 2-arachidonoylglycerol, the major CNS endocannabinoid, in the modulation of chondroitin sulfate proteoglycan accumulation in Theiler's murine encephalomyelitis virus-induced demyelinating disease. The treatment during the chronic phase with a potent reversible inhibitor of the enzyme monoacylglycerol lipase, which accounts for 85% of the 2-arachidonoylglycerol degradation in the mouse CNS, modulates neuroinflammation and reduces chondroitin sulfate proteoglycan deposition around demyelinated lesions in the spinal cord of Theiler's murine encephalomyelitis virus-infected mice. The increased 2-arachidonoylglycerol tone promotes remyelination in a model of progressive multiple sclerosis ameliorating motor dysfunction.
Copyright © 2017 the authors 0270-6474/17/378385-14$15.00/0.

Entities:  

Keywords:  2-AG; TMEV-IDD; chondroitin sulfate proteoglycans; neuroinflammation; oligodendrocytes; remyelination

Mesh:

Substances:

Year:  2017        PMID: 28751457      PMCID: PMC6596867          DOI: 10.1523/JNEUROSCI.2900-16.2017

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  56 in total

1.  Progenitor cells of the adult mouse subventricular zone proliferate, migrate and differentiate into oligodendrocytes after demyelination.

Authors:  B Nait-Oumesmar; L Decker; F Lachapelle; V Avellana-Adalid; C Bachelin; A Baron-Van Evercooren
Journal:  Eur J Neurosci       Date:  1999-12       Impact factor: 3.386

2.  Therapeutic action of cannabinoids in a murine model of multiple sclerosis.

Authors:  Angel Arévalo-Martín; José Miguel Vela; Eduardo Molina-Holgado; José Borrell; Carmen Guaza
Journal:  J Neurosci       Date:  2003-04-01       Impact factor: 6.167

3.  Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis.

Authors:  Ansi Chang; Wallace W Tourtellotte; Richard Rudick; Bruce D Trapp
Journal:  N Engl J Med       Date:  2002-01-17       Impact factor: 91.245

4.  Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling.

Authors:  Eduardo Molina-Holgado; José M Vela; Angel Arévalo-Martín; Guillermina Almazán; Francisco Molina-Holgado; José Borrell; Carmen Guaza
Journal:  J Neurosci       Date:  2002-11-15       Impact factor: 6.167

5.  Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis.

Authors:  A E Warrington; K Asakura; A J Bieber; B Ciric; V Van Keulen; S V Kaveri; R A Kyle; L R Pease; M Rodriguez
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

6.  Dexamethasone regulation of interleukin-1-receptors in the hippocampus of Theiler's virus-infected mice: effects on virus-mediated demyelination.

Authors:  A Lledó; J Borrell; C Guaza
Journal:  Eur J Pharmacol       Date:  1999-05-07       Impact factor: 4.432

7.  White matter extracellular matrix chondroitin sulfate/dermatan sulfate proteoglycans in multiple sclerosis.

Authors:  R A Sobel; A S Ahmed
Journal:  J Neuropathol Exp Neurol       Date:  2001-12       Impact factor: 3.685

Review 8.  Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy.

Authors:  H Lassmann; W Brück; C Lucchinetti
Journal:  Trends Mol Med       Date:  2001-03       Impact factor: 11.951

9.  Experimental autoimmune encephalomyelitis mobilizes neural progenitors from the subventricular zone to undergo oligodendrogenesis in adult mice.

Authors:  Nathalie Picard-Riera; Laurence Decker; Cécile Delarasse; Karine Goude; Brahim Nait-Oumesmar; Roland Liblau; Danielle Pham-Dinh; Anne Baron-Van Evercooren
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-16       Impact factor: 11.205

Review 10.  Why does remyelination fail in multiple sclerosis?

Authors:  Robin J M Franklin
Journal:  Nat Rev Neurosci       Date:  2002-09       Impact factor: 34.870

View more
  16 in total

1.  Activating cannabinoid receptor 2 preserves axonal health through GSK-3β/NRF2 axis in adrenoleukodystrophy.

Authors:  Janani Parameswaran; Leire Goicoechea; Laura Planas-Serra; Antoni Pastor; Montserrat Ruiz; Noel Y Calingasan; Cristina Guilera; Ester Aso; Jordi Boada; Reinald Pamplona; Manuel Portero-Otín; Rafael de la Torre; Isidre Ferrer; Carlos Casasnovas; Aurora Pujol; Stéphane Fourcade
Journal:  Acta Neuropathol       Date:  2022-07-01       Impact factor: 15.887

2.  Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice.

Authors:  Aníbal Sánchez-de la Torre; Tania Aguado; Alba Huerga-Gómez; Silvia Santamaría; Antonietta Gentile; Juan Carlos Chara; Carlos Matute; Krisztina Monory; Susana Mato; Manuel Guzmán; Beat Lutz; Ismael Galve-Roperh; Javier Palazuelos
Journal:  Cell Death Dis       Date:  2022-07-07       Impact factor: 9.685

3.  Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.

Authors:  Andrea Manterola; Ana Bernal-Chico; Raffaela Cipriani; Manuel Canedo-Antelo; Álvaro Moreno-García; Mar Martín-Fontecha; Fernando Pérez-Cerdá; María Victoria Sánchez-Gómez; Silvia Ortega-Gutiérrez; J Mark Brown; Ku-Lung Hsu; Benjamin Cravatt; Carlos Matute; Susana Mato
Journal:  Biochem Pharmacol       Date:  2018-08-01       Impact factor: 5.858

Review 4.  Medical Use of Cannabinoids.

Authors:  Ana Isabel Fraguas-Sánchez; Ana Isabel Torres-Suárez
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

Review 5.  Dynamic glial response and crosstalk in demyelination-remyelination and neurodegeneration processes.

Authors:  Tianci Chu; Lisa B E Shields; Wenxin Zeng; Yi Ping Zhang; Yuanyi Wang; Gregory N Barnes; Christopher B Shields; Jun Cai
Journal:  Neural Regen Res       Date:  2021-07       Impact factor: 5.135

6.  Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis.

Authors:  Fernando Laso-García; Jaime Ramos-Cejudo; Francisco Javier Carrillo-Salinas; Laura Otero-Ortega; Ana Feliú; MariCarmen Gómez-de Frutos; Miriam Mecha; Exuperio Díez-Tejedor; Carmen Guaza; María Gutiérrez-Fernández
Journal:  PLoS One       Date:  2018-09-19       Impact factor: 3.240

Review 7.  The Endocannabinoid System and Oligodendrocytes in Health and Disease.

Authors:  Alexander A Ilyasov; Carolanne E Milligan; Emily P Pharr; Allyn C Howlett
Journal:  Front Neurosci       Date:  2018-10-26       Impact factor: 4.677

8.  Manipulation of Gut Microbiota Influences Immune Responses, Axon Preservation, and Motor Disability in a Model of Progressive Multiple Sclerosis.

Authors:  Leyre Mestre; Francisco Javier Carrillo-Salinas; Miriam Mecha; Ana Feliú; Carmen Espejo; José Carlos Álvarez-Cermeño; Luisa María Villar; Carmen Guaza
Journal:  Front Immunol       Date:  2019-06-14       Impact factor: 7.561

9.  Asymmetrical 3D Nanoceria Channel for Severe Neurological Defect Regeneration.

Authors:  Yun Qian; Qixin Han; Xiaotian Zhao; Hui Li; Wei-En Yuan; Cunyi Fan
Journal:  iScience       Date:  2019-01-14

Review 10.  Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review.

Authors:  Miriam Mecha; Francisco J Carrillo-Salinas; Ana Feliú; Leyre Mestre; Carmen Guaza
Journal:  Front Cell Neurosci       Date:  2020-02-19       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.